# FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer

> **NCT00020202** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Extensive Stage Small Cell Lung Cancer
- Stage IIIA Non-small Cell Lung Cancer
- Stage IV Non-small Cell Lung Cancer
- Recurrent Small Cell Lung Cancer
- Stage IIIB Non-small Cell Lung Cancer
- Recurrent Non-small Cell Lung Cancer

## Interventions

- **DRUG:** FR901228

## Key facts

- **NCT ID:** NCT00020202
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-06
- **Primary completion:** —
- **Final completion:** 2007-03
- **Target enrollment:** — (—)
- **Last updated:** 2024-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00020202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00020202, "FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00020202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*